Pivotal Data Boost Omeros’ Stem Cell Transplant Product After FDA Delay

Narsoplimab Likely To Be First Drug For Treating HSCT-TMA

15 Jun 2021

• By Sten Stovall

Promising pivotal data boost chances for Omeros’ narsoplimab to become a highly needed, first-to-market drug for the treatment of a deadly complication of stem cell transplants.

Omeros announced results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy • Source: Alamy

Omeros Corporation’s hopes of launching its investigational product, narsoplimab, as a treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) were reinforced by positive pivotal data presented a this year’s European Hematology Association meeting.

The virtual presentation on 11 June showed good organ function improvement in high-risk patients treated with the product, and underscored...